PM
BPMC

Prosight Management’s Blueprint Medicines BPMC Stock Holding History

Prosight Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,512
Closed -$3.23M – 42
2025
Q1 		$3.23M Sell
36,512
-30,488
-46% -$2.97M 1.06% 25
2024
Q4 		$5.84M Buy
67,000
+19,900
+42% +$1.82M 1.62% 20
2024
Q3 		$4.36M Buy
+47,100
New +$4.68M 1.07% 28

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's BPMC Position: Q2 2025 in Review

Prosight Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 36,512 shares — an estimated $3.23M sold.

Prosight Management first reported a position in BPMC in Q3 2024 and held it in 3 quarters. The position peaked at $5.84M in Q4 2024. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Prosight Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Prosight Management sold 36,512 Blueprint Medicines shares in Q2 2025, an estimated $3.23M.
  • Prosight Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 3 quarters.
  • Prosight Management's Blueprint Medicines position peaked at $5.84M in Q4 2024.
  • 355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.